Objective: The rate of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma is high. Seeding upper urinary tract urothelial carcinoma cells onto the damaged bladder wall is considered to be one of the causes of intravesical recurrence after radical nephroureterectomy. We evaluated the utility of early ureteral ligation in preventing the intravesical recurrence. Methods: This prospective single-arm clinical trial included patients who underwent radical nephroureterectomy for upper urinary tract urothelial carcinoma in the Tohoku Urological Evidence-Based Medicine Study Group between 2012 and 2013. Early ureteral ligation was defined as ligation of the ureter as quickly as possible after expanding the retroperitoneal space. A historical control was extracted from 454 patients who underwent radical nephroureterectomy in the same group, using propensity score-matched analysis. Intravesical recurrence-free survival rates were analyzed using Kaplan-Meier curves. Factors predicting intravesical recurrence were assessed using multivariate analyses. Results: Seventy-four patients underwent early ureteral ligation. Seventeen (23%) patients had intravesical recurrence with a median follow-up period of 24 months. The 1-and 2-year intravesical recurrence-free survival rates in the early ureteral ligation group were 81% and 76%, and in the control group 75% and 63%, respectively (P = 0.160). In patients with renal pelvic cancer, the 1-and 2-year intravesical recurrence-free survival rates in the early ureteral ligation group were 89% and 86%, but in the control group 74% and 64%, respectively (P = 0.025). However, © The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 870 intravesical recurrence-free survival rates were similar in patients with ureteral cancer. Multivariate analyses of a subset of patients with renal pelvic cancer identified early ureteral ligation as an independent predictor of intravesical recurrence. Conclusions: Early ureteral ligation decreases the rate of intravesical recurrence after radical nephroureterectomy in patients with renal pelvic cancer. Thus, early ureteral ligation might help in prevention of intravesical recurrence for renal pelvic cancer.
Introduction
Radical nephroureterectomy (RNU) is the standard treatment for upper urinary tract urothelial carcinoma (UTUC). The rate of intravesical recurrence (IVR) after RNU for UTUC is, however, high (1) (2) (3) . IVR after RNU possibly results from field cancerization and/or intravesical seeding of UTUC. Field cancerization as a mechanism of IVR is supported by the results of a molecular study of UTUC and recurrent bladder tumors (4) , while intravesical seeding of UTUC has been reported by several studies (5, 6) . Patients with positive preoperative urine cytology frequently have IVR (5) . We previously reported that most IVRs occurred around the site of bladder mucosal injury, including at the cystotomy, the bladder neck or the posterior wall that was in contact with the indwelling urethral catheter, within one year after RNU (6) . These results suggest that UTUC cells seed on the bladder mucosa during RNU.
Prevention of UTUC seeding plays a critical role in the reduction of IVR after RNU. Recently, intravesical instillation therapy after RNU is recommended to prevent IVR (7) . The efficacy of intravesical instillation therapy is supported by two prospective Phase II trials for UTUC (8, 9) . One trial showed that a single dose of intravesical mitomycin C following RNU reduced the risk of IVR from 27% to 16% at 1 year (8) . Another trial from our study group demonstrated that a single instillation of pirarubicin ((2′R)-4′-O-tetrahydropyranyldoxorubicin; THP) significantly reduced the rates of IVR after RNU from 31.8% to 16.9% at 1 year (9) . Intravesical instillation of THP, which was performed within 48 h after RNU, might, thus, be effective in preventing the seeding of floating urothelial carcinoma cells. However, larger prospective trials are needed to confirm the effectiveness of intravesical instillation therapy.
It is, thus, conceivable that to minimize IVR after RNU, it is important to prevent the seeding of floating UTUC cells during RNU. During RNU, the ureter is usually, or not, ligated after ligation of the renal artery. If seeding of UTUC cells on the damaged bladder wall during RNU is a cause of IVR, ligating the ureter as quickly as possible after expanding the retroperitoneal space might be reasonable. A previous retrospective study focused on early ureteral ligation (EUL) during hand-assisted retroperitoneoscopic nephroureterectomy for primary renal pelvic cancer (10) . The study showed that EUL did not affect the IVR-free rate after RNU, although the time to the first IVR in patients without EUL was significantly shorter than in patients with EUL. The impact of EUL on IVR after RNU, therefore, remains controversial. Thus, we prospectively evaluated the utility of EUL in prevention of IVR after RNU for UTUC in a multicenter clinical trial.
Patients and methods
Patients who underwent RNU with bladder cuff resection for UTUC between 2012 and 2013 at 15 institutions participating in the Tohoku Urological Evidence-Based Medicine Study Group were enrolled in this study. Those who had past or present history of bladder cancer or distant metastasis were excluded from study participation. The study protocol was approved by the Ethics Committee of Tohoku University Hospital. Informed consent was obtained from all participants.
RNU was performed via a standard open or laparoscopic approach. Cuff resection of the bladder wall was performed via a lower abdominal incision, and the distal ureter and orifice were excised. We defined EUL as ligation of the ureter as quickly as possible after expansion of the retroperitoneal space and before ligation of the renal artery. The ureter was ligated caudal to the site of the tumor, except in cases with a distal ureteral tumor, in which case the ureter was ligated cephalad to the tumor.
The data evaluated included clinicopathological features and outcomes. Tumors were staged according to the 2009 International Union Against Cancer TNM classification (11) . Computed tomography or magnetic resonance imaging was used for imaging diagnosis. All surgical specimens were processed by pathologists using standard pathological procedures at each institution.
Cystoscopy and urinary cytology were repeated every 3 months for 2 years after RNU to evaluate IVR. The follow-up period was defined as the time from the day of RNU to the last day the patient was assessed. Pathologically confirmed bladder cancer after RNU occurring during the follow-up period was classified as IVR. In cases with IVR, the location of the recurrent tumor in the bladder was recorded as described in a previous report (9) .
A historical control was extracted from 454 patients who underwent RNU for UTUC in the same Tohoku study group between 2000 and 2011, using propensity score-matched analysis including gender, age, tumor side, tumor location, urinary cytology, stage, grade, carcinoma in situ and THP intravesical instillation. But, the surgical approach excluded from the factors using propensity scorematched analysis because of the different surgical period. The primary endpoint of this trial was the rate of IVR after RNU. The rate of IVR in the control group was estimated to be 35%. Sixty-nine patients were required to achieve 80% power of detecting a 15% difference at the 5% level of two-sided significance. In both groups, IVR-free survival rates after RNU were estimated using the KaplanMeier method, and the log-rank test was used to compare the data. Multivariate analyses using Cox regression models were performed to identify predictors of IVR after RNU. A probability value of less than 0.05 was considered statistically significant.
Results
A total of 78 patients were initially registered in this study. Four of them were excluded; three because they did not undergo ureteral ligation during RNU and one patient who had lung cancer. A total of 74 patients were eligible for this study and underwent EUL around the iliac artery before ligation of the renal artery. The median time from start of surgery to EUL was 4 5 min (range 14-127 min), and the median time from EUL to ligation of the renal artery was 50 min (range 2-179 min). The characteristics of the patients are shown in Table 1 . Forty-five patients had tumors in the renal pelvis, 27 patients in the ureter, and two patients in both renal pelvis and ureter. The median follow-up after RNU was 24 months (range 9-45 months). Two patients died from UTUC.
For the control group, 74 patients were extracted from 454 patients who underwent RNU for UTUC in the same group between 2000 and 2011, using propensity score-matched analysis including gender, age, tumor side, tumor site, urinary cytology, stage, grade, carcinoma in situ and THP intravesical instillation. The patients in the control group did not receive the ureteral ligation before ligation of the renal artery. The number of laparoscopic RNU was smaller in the control group than in the EUL group. The clinicopathological characteristics of patients in the control group were similar to those in the EUL group, except for the surgical approach (Table 1) .
IVR after RNU occurred in 17 (23%) patients in the EUL group and 27 (36%) patients in the control group, respectively. The 1-and 2-year IVR-free survival rates were 81% and 76%, respectively, in the EUL group; and 75% and 63%, respectively, in the control group (P = 0.160, Fig. 1 ). Of the 17 patients with IVR in the EUL group, IVR occurred at multiple sites in four patients. IVR after RNU occurred around the cystotomy (the orifice of the resected ureter), at the posterior wall, and at the bladder neck, in 10 (14%), 5 (7%) and 4 (5%) patients, respectively. On the other hand, IVR after RNU was first seen at the contralateral side in two patients (3%). No cases of IVR at the bladder dome or anterior wall were observed in this study. In the control group, IVR occurred at multiple sites in 12 of 27 patients. IVR occurred around the cystotomy, at the posterior wall, and at the bladder neck, in 12 (16%), 12 (16%), and 11 (15%) patients, respectively.
Among patients with renal pelvic cancer, the 1-and 2-year IVRfree survival rates were 89% and 86%, respectively, in the EUL group; and 74% and 64%, respectively, in the control group (P = 0.025, Fig. 2A) . However, in patients with ureteral cancer, the 1-and 2-year IVR-free survival rates were 67% and 61%, respectively, in the EUL group; and 80% and 61%, respectively, in the control group (P = 0.696, Fig. 2B ). Moreover, IVR-free survival rates after RNU were compared to address a distinct effect of EUL in a subset of patients without THP intravesical instillation. In patients with renal pelvic cancer, the 1-and 2-year IVR-free survival rates in the EUL group were 86% and 86%, but in the control group 73% and 61%, respectively (P = 0.033, Fig. 3A) . However, in patients with ureteral cancer, IVR-free survival rates for both groups were similar (P = 0.661, Fig. 3B ).
In multivariate analyses, gender (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.18-0.83, P = 0.013) was an independent predictor of IVR after RNU (Table 2) . Interestingly, multivariate analyses of a subset of patients with renal pelvic cancer identified EUL as an independent predictor of IVR after RNU (HR 0.33, CI 0.11-0.88, P = 0.027).
Discussion
In the present study, 23% of patients with EUL developed IVR after RNU for UTUC. The 1-and 2-year IVR-free survival rates were 81% and 76%, respectively. The proportion of laparoscopic RNU was significantly higher in the EUL group than in the control group because of the different surgical period. Some studies have shown that the laparoscopic approach is an independent predictor of IVR after RNU (12, 13) , possibly due to the influence of kidney manipulation and the high abdominal pressure intraoperatively, resulting in intraluminal seeding and implantation of cancer cells. A recent systematic review and meta-analysis also demonstrated that there was an increased risk of IVR in patients with laparoscopic RNU (3), whereas Ni et al. reported that the rates of IVR after RNU were lower in laparoscopic approach group than in open group (14) . However, comparison with the control group using propensity score-matched analysis indicated that EUL resulted in 6% and 13% improvements in 1-and 2-year IVR-free survival rates, respectively. Only a few prospective randomized trials on IVR after RNU have been reported so far (8, 9) . One trial was performed in the same Tohoku Urological Evidence-Based Medicine Study Group (9). The IVR-free survival rates at 1 and 2 years in the control group were 68.2% and 57.8% in that report, respectively. In another trial of a single postoperative intravesical dose of mitomycin C performed by O'Brien et al. (8) , the IVR rate at 1 year was 27% in the standard treatment group. However, since the characteristics of the patients in that study were different from ours, their results cannot be directly compared with ours. Yet, our results indicate that EUL has the potential to decrease the IVR rate after RNU.
In our study, EUL significantly improved IVR-free survival rates in patients with renal pelvic cancer. A retrospective study showed that the mean time to IVR after hand-assisted retroperitoneoscopic nephroureterectomy for renal pelvic cancer was 11.7 and 26.4 months in patients without and with EUL, respectively (10) . Another study demonstrated that clipping of the distal ureter at the beginning of RNU significantly reduced IVR from 34.9% to 14.7% (15) . In that study, most IVRs occurred within one year after RNU in the patients without EUL, which was similar to that seen in the present study.
The most common site of first IVR was around the cystotomy in our study, which is similar to observations from previous reports (5,6). It is reported that an intact urothelium has the ability to resist tumor cell adherence, while injured urothelium can serve as a site of adherence (16, 17) . Urothelial carcinoma cells can easily adhere to the sites of urothelial injury, such as the cystotomy site. Moreover, IVR-free survival rates were similar in the patients with ureteral cancer in this study. Ureteral cancer might be floated down during RNU since the ureter was ligated cephalad to the ureteral tumor. These results suggest that EUL might prevent cancer cells from floating down during RNU in the patients with renal pelvic cancer, but not in the patients with ureteral cancer.
There is a concern that EUL might elevate the inner pressure of the renal pelvis, which might result in UTUC cells pushing out into the lymphovascular system, contributing to the metastasis. However, Ou et al. reported that EUL had no adverse effect on the cancerspecific survival (10) . Their study was retrospective in nature and included a small study population. In our study, two patients in the EUL group died from UTUC, but they had muscle-invasive UTUC. Since the follow-up after RNU was unfortunately short to evaluate the prognosis of UTUC patients undergoing EUL, the follow-up period need to be further extended.
The present study has several limitations. This was a prospective study which involved a single-arm and propensity score-matched analysis. Although the period background was different, we performed RNU for UTUC at the same study group and the procedure of RNU alone was not different. However, larger prospective trials with longer follow-up periods need to be conducted in future, to confirm the findings of this study. In this study, a central pathological review was not performed; instead, pathological diagnosis was carried out by pathologists at each institution. Also, some patients underwent perioperative chemotherapy in the present study. Perioperative chemotherapy was not an independent predictor of IVR in the present study, which is similar to observations from previous retrospective reports (3, 9) . Larger prospective trials should be conducted to clarify the efficacy of perioperative systemic chemotherapy. Finally, only 15% of patients received THP intravesical instillation after RNU. Two Phase II trials for UTUC (8, 9) showed the benefit in reducing IVR after RNU. However, the intravesical instillation after RNU was not established when this study was begun. A prospective Phase III trial of THP intravesical instillation is currently underway.
In conclusion, EUL decreases the rate of IVR after RNU in patients with renal pelvic cancer. This might result from the prevention of floating UTUC cells during RNU. Thus, EUL might help to prevent IVR after RNU for renal pelvic cancer. 
